



# Institute for Protein Innovation

*Let our proteins power your next discovery*

## About us

The Institute for Protein Innovation (IPI) is a nonprofit research organization co-founded in 2017 by Harvard Medical School professors Tim Springer and Andrew Kruse. Its mission is to advance protein science to accelerate research and improve human health.

Surrounded by the momentum of genomics but immersed in protein science, Springer understood the need to connect the many genes uncovered by the Human Genome Project to their ultimate function in the body via proteins. He founded IPI to fuel a next generation of protein science that might fill the gaps genomics cannot reach.

Specifically, IPI is providing scientists with antibodies and other protein tools, as well as the expertise to use those tools to illuminate fundamental biological processes and therapeutic leads. The Institute also advances protein science by supporting applied protein research, technology development and educational outreach in the life sciences.

Anchored by Springer's philanthropy, IPI stands apart from traditional life science companies in its freedom to pursue long-term and high-risk projects without funding limitations or profit constraints. The Institute is uniquely sustained by revenue from its antibody distribution, sponsored research and federal funding.

## Quick facts

- IPI was founded in 2017 by scientists Tim Springer and Andrew Kruse of Harvard Medical School.
- The Institute is headquartered on the Harvard Medical School campus.
- IPI is making synthetic recombinant antibodies and distributing them to scientists through its nonprofit partner Addgene.
- IPI is financially secured by substantial gifts from co-founder Tim Springer, revenue from antibody distribution, sponsored research and federal funding.
- IPI is a nonprofit 501(c)3 organization.



Let our proteins power your next discovery.



## What is IPI working on?

At IPI's core is a scientific platform producing synthetic, recombinant antibodies against sets of related extracellular and secreted protein targets. Combining yeast display technology with rigorous quality control, the Institute targets highly conserved proteins that have eluded traditional animal-derived antibodies.

IPI also aims to address the scientific reproducibility crisis and the lack of comprehensive information provided with typical reagent antibodies. IPI validates its antibodies in key research applications with standardized protocols based on user feedback to create a repertoire of reproducible and well-validated protein tools.

## The opportunity

At IPI, we see a critical need for:

- **Cutting-edge protein science** to enable new tools and technologies that support biomedical discovery and therapeutic development.
- **A home for talented protein engineers and technology-focused scientists** to better convene and innovate without the constraints of an academic or industrial setting.
- **Access to reproducible, well-characterized antibodies** and information on the conditions and contexts in which to use them.

*IPI is poised to address these unmet needs through its nonprofit status, organizational structure, expertise and strategy.*